complement system inhibitors Search Results


fxi  (Athens Research)
92
Athens Research fxi
(A) Non-reducing Western blot analysis of <t>FXI,</t> C1inh, and transferrin loading control in plasma of 10 AD patients and 10 ND controls from Group 1. Lanes loaded with <t>FXI</t> <t>purified</t> protein (FXI) and FXI-deficient human plasma (FXI-def) show that the band just above the FXI band is non-specific. (B) FXI levels normalized to transferrin were lower in AD than ND plasma (p = 0.008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (C) C1inh levels were lower in AD than ND plasma (p = 0.0008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (D) Levels of FXI, C1inh, and transferrin were analyzed in 10 AD and 10 ND plasmas from Group 2. (E) FXI levels were lower in AD than ND plasma (p = 0.0003). (F) C1inh levels were lower in AD than ND plasma (p = 0.01). (G) Levels of fibrin monomer were analyzed under reducing conditions in 10 AD and 10 ND plasma samples from Group 2 using antibody 59D8 specific for fibrin beta chain [46]. (H) D-dimer levels were analyzed under non-reducing conditions in 10 AD and 10 ND plasma samples from Group 2. (I) Fibrin (p = 0.009) and D-dimer (p = 0.018) levels were increased in Group 2 AD plasma compared to control. (J) Fibrin (r = −0.49; p = 0.03) and D-dimer (r = −0.57, p = 0.008) levels were negatively correlated with FXI levels in samples from Group 2.
Fxi, supplied by Athens Research, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fxi/product/Athens Research
Average 92 stars, based on 1 article reviews
fxi - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
elisa kit  (Shanghai Korain Biotech Co Ltd)
90
Shanghai Korain Biotech Co Ltd elisa kit
(A) Non-reducing Western blot analysis of <t>FXI,</t> C1inh, and transferrin loading control in plasma of 10 AD patients and 10 ND controls from Group 1. Lanes loaded with <t>FXI</t> <t>purified</t> protein (FXI) and FXI-deficient human plasma (FXI-def) show that the band just above the FXI band is non-specific. (B) FXI levels normalized to transferrin were lower in AD than ND plasma (p = 0.008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (C) C1inh levels were lower in AD than ND plasma (p = 0.0008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (D) Levels of FXI, C1inh, and transferrin were analyzed in 10 AD and 10 ND plasmas from Group 2. (E) FXI levels were lower in AD than ND plasma (p = 0.0003). (F) C1inh levels were lower in AD than ND plasma (p = 0.01). (G) Levels of fibrin monomer were analyzed under reducing conditions in 10 AD and 10 ND plasma samples from Group 2 using antibody 59D8 specific for fibrin beta chain [46]. (H) D-dimer levels were analyzed under non-reducing conditions in 10 AD and 10 ND plasma samples from Group 2. (I) Fibrin (p = 0.009) and D-dimer (p = 0.018) levels were increased in Group 2 AD plasma compared to control. (J) Fibrin (r = −0.49; p = 0.03) and D-dimer (r = −0.57, p = 0.008) levels were negatively correlated with FXI levels in samples from Group 2.
Elisa Kit, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit/product/Shanghai Korain Biotech Co Ltd
Average 90 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
clu  (Proteintech)
93
Proteintech clu
(A) Non-reducing Western blot analysis of <t>FXI,</t> C1inh, and transferrin loading control in plasma of 10 AD patients and 10 ND controls from Group 1. Lanes loaded with <t>FXI</t> <t>purified</t> protein (FXI) and FXI-deficient human plasma (FXI-def) show that the band just above the FXI band is non-specific. (B) FXI levels normalized to transferrin were lower in AD than ND plasma (p = 0.008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (C) C1inh levels were lower in AD than ND plasma (p = 0.0008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (D) Levels of FXI, C1inh, and transferrin were analyzed in 10 AD and 10 ND plasmas from Group 2. (E) FXI levels were lower in AD than ND plasma (p = 0.0003). (F) C1inh levels were lower in AD than ND plasma (p = 0.01). (G) Levels of fibrin monomer were analyzed under reducing conditions in 10 AD and 10 ND plasma samples from Group 2 using antibody 59D8 specific for fibrin beta chain [46]. (H) D-dimer levels were analyzed under non-reducing conditions in 10 AD and 10 ND plasma samples from Group 2. (I) Fibrin (p = 0.009) and D-dimer (p = 0.018) levels were increased in Group 2 AD plasma compared to control. (J) Fibrin (r = −0.49; p = 0.03) and D-dimer (r = −0.57, p = 0.008) levels were negatively correlated with FXI levels in samples from Group 2.
Clu, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/clu/product/Proteintech
Average 93 stars, based on 1 article reviews
clu - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
anti apolipoprotein j clusterin antibody  (Boster Bio)
90
Boster Bio anti apolipoprotein j clusterin antibody
(A) Non-reducing Western blot analysis of <t>FXI,</t> C1inh, and transferrin loading control in plasma of 10 AD patients and 10 ND controls from Group 1. Lanes loaded with <t>FXI</t> <t>purified</t> protein (FXI) and FXI-deficient human plasma (FXI-def) show that the band just above the FXI band is non-specific. (B) FXI levels normalized to transferrin were lower in AD than ND plasma (p = 0.008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (C) C1inh levels were lower in AD than ND plasma (p = 0.0008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (D) Levels of FXI, C1inh, and transferrin were analyzed in 10 AD and 10 ND plasmas from Group 2. (E) FXI levels were lower in AD than ND plasma (p = 0.0003). (F) C1inh levels were lower in AD than ND plasma (p = 0.01). (G) Levels of fibrin monomer were analyzed under reducing conditions in 10 AD and 10 ND plasma samples from Group 2 using antibody 59D8 specific for fibrin beta chain [46]. (H) D-dimer levels were analyzed under non-reducing conditions in 10 AD and 10 ND plasma samples from Group 2. (I) Fibrin (p = 0.009) and D-dimer (p = 0.018) levels were increased in Group 2 AD plasma compared to control. (J) Fibrin (r = −0.49; p = 0.03) and D-dimer (r = −0.57, p = 0.008) levels were negatively correlated with FXI levels in samples from Group 2.
Anti Apolipoprotein J Clusterin Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti apolipoprotein j clusterin antibody/product/Boster Bio
Average 90 stars, based on 1 article reviews
anti apolipoprotein j clusterin antibody - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
human clusterin elisa kit  (Boster Bio)
93
Boster Bio human clusterin elisa kit
CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using <t>ELISA</t> after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.
Human Clusterin Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human clusterin elisa kit/product/Boster Bio
Average 93 stars, based on 1 article reviews
human clusterin elisa kit - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
monoclonal antibody  (Boster Bio)
90
Boster Bio monoclonal antibody
CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using <t>ELISA</t> after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.
Monoclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal antibody/product/Boster Bio
Average 90 stars, based on 1 article reviews
monoclonal antibody - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
therapeutic complement inhibitors  (Achillion inc)
90
Achillion inc therapeutic complement inhibitors
CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using <t>ELISA</t> after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.
Therapeutic Complement Inhibitors, supplied by Achillion inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/therapeutic complement inhibitors/product/Achillion inc
Average 90 stars, based on 1 article reviews
therapeutic complement inhibitors - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
therapeutic inhibitors for the lectin activation pathway of complement  (Omeros Inc)
90
Omeros Inc therapeutic inhibitors for the lectin activation pathway of complement
CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using <t>ELISA</t> after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.
Therapeutic Inhibitors For The Lectin Activation Pathway Of Complement, supplied by Omeros Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/therapeutic inhibitors for the lectin activation pathway of complement/product/Omeros Inc
Average 90 stars, based on 1 article reviews
therapeutic inhibitors for the lectin activation pathway of complement - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
complement pathway inhibitor  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies complement pathway inhibitor
CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using <t>ELISA</t> after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.
Complement Pathway Inhibitor, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/complement pathway inhibitor/product/Federation of European Neuroscience Societies
Average 90 stars, based on 1 article reviews
complement pathway inhibitor - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
complement cascade amd, geographic atrophy inhibitor (factor d  (Genentech inc)
90
Genentech inc complement cascade amd, geographic atrophy inhibitor (factor d
CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using <t>ELISA</t> after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.
Complement Cascade Amd, Geographic Atrophy Inhibitor (Factor D, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/complement cascade amd, geographic atrophy inhibitor (factor d/product/Genentech inc
Average 90 stars, based on 1 article reviews
complement cascade amd, geographic atrophy inhibitor (factor d - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
complement inhibitors  (Diamedix Corporation)
90
Diamedix Corporation complement inhibitors
CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using <t>ELISA</t> after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.
Complement Inhibitors, supplied by Diamedix Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/complement inhibitors/product/Diamedix Corporation
Average 90 stars, based on 1 article reviews
complement inhibitors - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
complement inhibitors avacincaptad  (IVERIC Bio Inc)
90
IVERIC Bio Inc complement inhibitors avacincaptad
CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using <t>ELISA</t> after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.
Complement Inhibitors Avacincaptad, supplied by IVERIC Bio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/complement inhibitors avacincaptad/product/IVERIC Bio Inc
Average 90 stars, based on 1 article reviews
complement inhibitors avacincaptad - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


(A) Non-reducing Western blot analysis of FXI, C1inh, and transferrin loading control in plasma of 10 AD patients and 10 ND controls from Group 1. Lanes loaded with FXI purified protein (FXI) and FXI-deficient human plasma (FXI-def) show that the band just above the FXI band is non-specific. (B) FXI levels normalized to transferrin were lower in AD than ND plasma (p = 0.008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (C) C1inh levels were lower in AD than ND plasma (p = 0.0008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (D) Levels of FXI, C1inh, and transferrin were analyzed in 10 AD and 10 ND plasmas from Group 2. (E) FXI levels were lower in AD than ND plasma (p = 0.0003). (F) C1inh levels were lower in AD than ND plasma (p = 0.01). (G) Levels of fibrin monomer were analyzed under reducing conditions in 10 AD and 10 ND plasma samples from Group 2 using antibody 59D8 specific for fibrin beta chain [46]. (H) D-dimer levels were analyzed under non-reducing conditions in 10 AD and 10 ND plasma samples from Group 2. (I) Fibrin (p = 0.009) and D-dimer (p = 0.018) levels were increased in Group 2 AD plasma compared to control. (J) Fibrin (r = −0.49; p = 0.03) and D-dimer (r = −0.57, p = 0.008) levels were negatively correlated with FXI levels in samples from Group 2.

Journal: Journal of thrombosis and haemostasis : JTH

Article Title: The Alzheimer’s disease peptide Aβ promotes thrombin generation through activation of coagulation factor XII

doi: 10.1111/jth.13209

Figure Lengend Snippet: (A) Non-reducing Western blot analysis of FXI, C1inh, and transferrin loading control in plasma of 10 AD patients and 10 ND controls from Group 1. Lanes loaded with FXI purified protein (FXI) and FXI-deficient human plasma (FXI-def) show that the band just above the FXI band is non-specific. (B) FXI levels normalized to transferrin were lower in AD than ND plasma (p = 0.008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (C) C1inh levels were lower in AD than ND plasma (p = 0.0008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25], and mean values for each group are designated by asterisk. (D) Levels of FXI, C1inh, and transferrin were analyzed in 10 AD and 10 ND plasmas from Group 2. (E) FXI levels were lower in AD than ND plasma (p = 0.0003). (F) C1inh levels were lower in AD than ND plasma (p = 0.01). (G) Levels of fibrin monomer were analyzed under reducing conditions in 10 AD and 10 ND plasma samples from Group 2 using antibody 59D8 specific for fibrin beta chain [46]. (H) D-dimer levels were analyzed under non-reducing conditions in 10 AD and 10 ND plasma samples from Group 2. (I) Fibrin (p = 0.009) and D-dimer (p = 0.018) levels were increased in Group 2 AD plasma compared to control. (J) Fibrin (r = −0.49; p = 0.03) and D-dimer (r = −0.57, p = 0.008) levels were negatively correlated with FXI levels in samples from Group 2.

Article Snippet: Purified FXI, C1 esterase inhibitor (Athens Research and Technology), and FXI-deficient plasma (George King Biomedical) served as controls.

Techniques: Western Blot, Control, Clinical Proteomics, Purification

CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using ELISA after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.

Journal: Scientific Reports

Article Title: Clusterin mediates hydroquinone-induced cytotoxic responses in HL-60 differentiated cells

doi: 10.1038/s41598-024-82140-0

Figure Lengend Snippet: CLU protein concentration in HL-60 cells exposed to different concentrations of HQ. CLU protein levels were quantified using ELISA after treatment with HQ at concentrations of 0, 10, 25, and 50 µmol/L ( n = 3 per group). The error bars represent SD, and the mean is shown as horizontal bars. The control group (0 µmol/L HQ) exhibited the highest CLU concentration (19.05 ± 2.32 ng/mL), while HQ-treated groups showed a progressive decrease: 14.45 ± 1.23 ng/mL at 10 µmol/L, 9.43 ± 0.40 ng/mL at 25 µmol/L, and 9.46 ± 0.67 ng/mL at 50 µmol/L. Significant differences were determined by ANOVA followed by Tukey post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05), ns : not significant.

Article Snippet: The concentration of sCLU proteins was measured using the Human Clusterin ELISA Kit (Boster Biological Technology, China) according to the instructions.

Techniques: Protein Concentration, Enzyme-linked Immunosorbent Assay, Control, Concentration Assay

Concentration of sCLU protein in the cell culture supernatant after exposure to varying HQ concentrations. The concentration of sCLU protein in the supernatant of HL -60 cell cultures was determined using ELISA following treatment with HQ at 0, 10, 25, and 50 µmol/L ( n = 3 per group). The control group (0 µmol/L HQ) exhibited the highest concentration (25.88 ± 4.24 ng/mL), while the 10 µmol/L HQ group showed a slight, non-significant decrease (23.73 ± 2.03 ng/mL, p = 0.696). Significant reductions were observed in the 25 µmol/L (17.45 ± 0.36 ng/mL) and 50 µmol/L (12.96 ± 0.67 ng/mL) groups compared to the control (* p < 0.05, *** p < 0.001, ns p > 0.05), ns : not significant.

Journal: Scientific Reports

Article Title: Clusterin mediates hydroquinone-induced cytotoxic responses in HL-60 differentiated cells

doi: 10.1038/s41598-024-82140-0

Figure Lengend Snippet: Concentration of sCLU protein in the cell culture supernatant after exposure to varying HQ concentrations. The concentration of sCLU protein in the supernatant of HL -60 cell cultures was determined using ELISA following treatment with HQ at 0, 10, 25, and 50 µmol/L ( n = 3 per group). The control group (0 µmol/L HQ) exhibited the highest concentration (25.88 ± 4.24 ng/mL), while the 10 µmol/L HQ group showed a slight, non-significant decrease (23.73 ± 2.03 ng/mL, p = 0.696). Significant reductions were observed in the 25 µmol/L (17.45 ± 0.36 ng/mL) and 50 µmol/L (12.96 ± 0.67 ng/mL) groups compared to the control (* p < 0.05, *** p < 0.001, ns p > 0.05), ns : not significant.

Article Snippet: The concentration of sCLU proteins was measured using the Human Clusterin ELISA Kit (Boster Biological Technology, China) according to the instructions.

Techniques: Concentration Assay, Cell Culture, Enzyme-linked Immunosorbent Assay, Control